Form 4: Erasca Director Acquires Stock Options in Lieu of 2025 Cash Compensation

Erasca director James Arthur Bristol acquired 45,678 stock options in lieu of cash compensation for his board service in 2025.

Summary

• James Arthur Bristol, a director at Erasca, Inc., acquired 45,678 stock options on January 1, 2025.
• These options were granted in lieu of cash compensation for his service on the board of directors and its committees in 2025.
• The options have an exercise price of $2.51 per share.
• The options will vest in monthly increments over 12 months, starting one month from the grant date, contingent on continued board service.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive alignment of interests between the director and the company. There is no indication of any negative sentiment.

Positives

• The director's acceptance of stock options in lieu of cash compensation demonstrates confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

This is a standard practice for compensating board members, particularly in growth-oriented companies, aligning their interests with shareholders through equity-based compensation.

Comparison to Industry Standards

• Granting stock options to board members is a common practice across the biotech industry, aligning their interests with the long-term success of the company.
• The vesting schedule of 12 months is also typical for such grants, ensuring continued service and commitment from the director.
• Companies like Amgen, Gilead, and Regeneron also use stock options as part of their board compensation packages.

Stakeholder Impact

• Shareholders may view this as a positive sign, as it aligns the director's interests with the company's long-term performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, director compensation, insider trading, Erasca, board of directors, equity, vesting